Myocardial dysfunction. in sepsis

Similar documents
Vasopressors. Judith Hellman, M.D. Associate Professor Anesthesia and Perioperative Care University of California, San Francisco

Inotropes/Vasoactive Agents Hina N. Patel, Pharm.D., BCPS Cathy Lawson, Pharm.D., BCPS

VASOPRESSOR AGENTS IN SEPTIC SHOCK

Septic Shock: Pharmacologic Agents for Hemodynamic Support. Nathan E Cope, PharmD PGY2 Critical Care Pharmacy Resident

Fundamentals of Critical Care: Hemodynamics, Monitoring, Shock

Inotrope and Vasopressor Therapy of Septic Shock

The Sepsis Puzzle: Identification, Monitoring and Early Goal Directed Therapy

Inflammatory or cardiogenic lung edema? It does matter!

Update on Small Animal Cardiopulmonary Resuscitation (CPR)- is anything new?

ANNE ARUNDEL MEDICAL CENTER CRITICAL CARE MEDICATION MANUAL DEPARTMENT OF NURSING AND PHARMACY. Guidelines for Use of Intravenous Isoproterenol

Guidelines for diagnosis and management of acute pulmonary embolism

Edwards FloTrac Sensor & Edwards Vigileo Monitor. Understanding Stroke Volume Variation and Its Clinical Application

Heart Failure EXERCISES. Ⅰ. True or false questions (mark for true question, mark for false question. If it is false, correct it.

Core Measures SEPSIS UPDATES

Rome Disclosure. The speaker cooperates with the following companies. BMeye Drager-Siemens Pulsion.

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South

Milwaukee School of Engineering Case Study: Factors that Affect Blood Pressure Instructor Version

Starling s Law Regulation of Myocardial Performance Intrinsic Regulation of Myocardial Performance

Treatment of cardiogenic shock

Introduction to CV Pathophysiology. Introduction to Cardiovascular Pathophysiology

Inpatient Code Sepsis March Update. Sarah Prebil

Chapter 16. Learning Objectives. Learning Objectives 9/11/2012. Shock. Explain difference between compensated and uncompensated shock

Low-gradient severe aortic stenosis with normal LVEF: A disturbing clinical entity

Arrest. What s a Nurse to do?

SE5h, Sepsis Education.pdf. Surviving Sepsis

Lecture Outline. Cardiovascular Physiology. Cardiovascular System Function. Functional Anatomy of the Heart

Decreasing Sepsis Mortality at the University of Colorado Hospital

Cardiovascular System & Its Diseases. Lecture #4 Heart Failure & Cardiac Arrhythmias

Medical Direction and Practices Board WHITE PAPER

Atrial Fibrillation in the ICU: Attempting to defend 4 controversial statements

Your Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007

STAGES OF SHOCK. IRREVERSIBLE SHOCK Heart deteriorates until it can no longer pump and death occurs.

Leanna R. Miller, RN, MN, CCRN-CMC, PCCN-CSC, CEN, CNRN, NP Education Specialist LRM Consulting Nashville, TN

Universitätsklinik für Kardiologie. Test. Thomas M. Suter Akute Herzinsuffizienz Diagnostik und Therapie 1

La valutazione dell emodinamica in corso di insufficienza renale acuta

Cardiogenic shock: invasive and non-invasive monitoring John T. Parissis Attikon University Hospital Athens, Greece

DIPHENHYDRAMINE (Benadryl)

Anaesthesia and Heart Failure

Inpatient Heart Failure Management: Risks & Benefits

Jeopardy Topics: THE CLOT STOPS HERE (anticoagulants) SUGAR, SUGAR, HOW D YOU GET SO HIGH (insulins)

Procedure for Inotrope Administration in the home

BUNDLES IN 2013: SURVIVING SEPSIS CAMPAIGN

Telemedicine Resuscitation & Arrest Trials (TreAT)

Acute heart failure may be de novo or it may be a decompensation of chronic heart failure.

Sepsis: Identification and Treatment

ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) S. Agarwal, MD, S. Kache MD

Traumatic Cardiac Tamponade. Shane KF Seal 19 November 2003 POS

Version Module guide. Preliminary document. International Master Program Cardiovascular Science University of Göttingen

INTRODUCTION TO EECP THERAPY

1 Congestive Heart Failure & its Pharmacological Management

Vasoactive drugs in the intensive care unit Cheryl L. Holmes

Dr Kenneth Tan. MBBS MMed(Anaes) MRCP(UK) EDIC FCCP Anesthesia and Intensive Care Services Mount Elizabeth Hospital

NEW ADVANCES IN MYOCARDIAL INFARCTION THERAPY: THE REGENERATION APPROACH

ATRIAL FIBRILLATION (RATE VS RHYTHM CONTROL)

What is the Future of Epinephrine in Cardiac Arrest? Pros and Cons

CENTER FOR DRUG EVALUATION AND RESEARCH

ACLS PHARMACOLOGY 2011 Guidelines

Cardiac Arrest VF/Pulseless VT Learning Station Checklist

Double pumping of intravenous vasoactive drugs in the critical care setting.

1p36 and the Heart. John Lynn Jefferies, MD, MPH, FACC, FAHA

Mr GH: Pericardial Window. Anaesthetic Management of Cardiac Tamponade

Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results

Cardiovascular System

Exchange solutes and water with cells of the body

Quiz 5 Heart Failure scores (n=163)

Pulmonary Hypertension in Sickle Cell Disease. Jorge Ramos Hematology Fellows Conference June 28, 2013

HYPERTENSION ASSOCIATED WITH RENAL DISEASES

Subject: Severe Sepsis/Septic Shock Published Date: August 9, 2013 Scope: Hospital Wide Original Creation Date: August 9, 2013

Sign up to receive ATOTW weekly

John Gasman, MD Alec Jamieson, RN, MSN Kim Clifforth, RN, BSN, MSN, CNS Thomas T. Lam, MD. June 18, 2013

Anatomi & Fysiologi The cardiovascular system (chapter 20) The circulation system transports; What the heart can do;

Sepsis Reassess patient Monitor and maintain respiratory/ hemodynamic status

The article is issued in the form of presentation presented at symposium

Section Four: Pulmonary Artery Waveform Interpretation

Disclosure. Learning Objectives 9/20/2012

VASOPRESSOR AND INOTROPE USAGE IN SHOCK

ELIGIBILITY CRITERIA FOR PULMONARY ARTERIAL HYPERTENSION THERAPY

Atrial Fibrillation Management Across the Spectrum of Illness

Norepinephrine supplemented with dobutamine or epinephrine for the cardiovascular support of patients with septic shock

MEDICATIONS USED IN ADULT CODE BLUE EMERGENCIES. Source: ACLS Provider Manual. American Heart Association. 2001, Updated 2003.

Cardiogenic Shock + Critical Aortic Stenosis = Run the Other Way?!!!

Diagnosis Code Crosswalk : ICD-9-CM to ICD-10-CM Cardiac Rhythm and Heart Failure Diagnoses

Year in Review 2012 Intensive Care. J.G. van der Hoeven or

Pharmacologic Stress Agents

Cancer Treatment and the Heart Cardio-Oncology September 12, 2014

The author has no disclosures

Riociguat Clinical Trial Program

Vtial sign #1: PULSE. Vital Signs: Assessment and Interpretation. Factors that influence pulse rate: Importance of Vital Signs

BCCA Protocol Summary for Palliative Treatment of Advanced Pancreatic Neuroendocrine Tumours using SUNItinib (SUTENT )

Cardiovascular Risk in Diabetes

Heart Disease: Diagnosis & Treatment

Cardiovascular diseases. pathology

SPECIALTY : CARDIOLOGY CLINICAL PROBLEM: HEART FAILURE

CHAPTER 5 DISCUSSION

Kardiogent shock. FYA-kursus 28. November 2006

Vs. K. Farsalinos, D. Tsiapras, S. Kyrzopoulos, M. Savvopoulou, E. Avramidou, D. Vassilopoulou, V. Voudris

Management of the Patient with Aortic Stenosis undergoing Non-cardiac Surgery

RISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department

Recommendations: Other Supportive Therapy of Severe Sepsis*

Glucagon stimulates adenyl cyclase. Amrinone and milrinone inhibit phosphodiesteras e

Transcription:

Myocardial dysfunction in sepsis Prof. Jean-Louis TEBOUL Medical ICU Bicetre hospital University Paris XI France

septic shock patients Early depression of LVEF that persisted for up to 4 days and returned to normal within 7-10 days in survivors Time days (days) Parker et al Ann Intern Med 1984

Sepsis-related cardiac dysfunction Incidence Mechanisms Diagnosis Treatment

LV EF % LV EF % LV EF % Day 1 Day 2 Day 3 after vasopressors weaning Day 1 Day 2 Day 3 after vasopressors weaning Day 1 Day 2 Day 3 after vasopressors weaning 40% of pts 40% of pts 20% of pts

Sepsis-related cardiac dysfunction Incidence Mechanisms Diagnosis Treatment

Mechanisms of sepsis-related cardiac dysfunction Supracellular mechanisms Intrinsic cellular mechanisms

Supracellular mechanisms Coronary blood flow Generally, coronary blood flow is not decreased during sepsis but in patients with prior coronary artery disease, avoid profound fall in diastolic blood pressure (driving pressure for left coronary blood flow)

Mechanisms of sepsis-related cardiac dysfunction Supracellular mechanisms Coronary blood flow Circulating factors

J Clin Invest 1985; 1539-1553 extent of shortening of rat myocardial cells Serum from septic shock patients contained substances that were able to depress cardiac contractility

J Clin Invest 1985; 1539-1553 70 60 recovery phase 50 40 30 20 10 0-10 acute phase -20-30 -40-50 -60-70 % changes in the extent of myocardial cell shortening Serum from septic shock patients contained substances In the recovery phase, this phenomenon no longer existed that were able to depress cardiac contractility

Mechanisms of sepsis-related cardiac dysfunction Supracellular mechanisms Coronary blood flow Circulating factors TNF-, IL 1, others?

absence of plasma Cardiac contractility can be decreased during sepsis in the absence of plasma. This argues against a major role of a circulating myocardial depressant factor but rather supports an intrinsic alteration in the myocardium as the predominant mechanism of septic cardiac dysfunction. After Rabuel and Mebazaa Intensive Care Med 2006

Mechanisms of sepsis-related cardiac dysfunction Supracellular mechanisms Intrinsic cellular mechanisms Coronary blood flow -adrenergic receptors Circulating factors

cardiomyocyte membrane 1 agonist camp 1 receptor AMP Adenylate cyclase + PKa Ca 2+ Tn myosin-actin bridges + cytosol Ca 2+ sarcoplasmic reticulum

Chest 1993; 103:81-85 3 2.5 2 Cardiac Index L/min/m 2 * * * 1.5 1 0 5 10 15 Dobutamine dose (µg/kg/min)

Crit Care Med 1993; 21:31-39 non severe sepsis septic shock Cardiac Index 6 5 4 * * ns L/min/m 2 3 2 0 5 10 0 5 10 dobutamine dose (µg/kg/min)

Crit Care Med 1993; 21:31-39 camp response to isoproterenol volunteers sepsis septic shock impairment of -adrenergic receptor responsiveness * * # sepsis, septic shock

Decreased efficacy of dobutamine in patients with septic shock Crit Care Med 1993; 21:31-39 camp response to isoproterenol volunteers sepsis septic shock * * # impairment of -adrenergic receptor responsiveness sepsis, septic shock camp response to Na-fluoride sepsis septic shock impairment of * # post -adrenergic receptor signal transduction septic shock

Mechanisms of sepsis-related cardiac dysfunction Supracellular mechanisms Intrinsic cellular mechanisms Coronary blood flow Circulating factors -adrenergic receptors Calcium and myofilaments

1 agonist camp cardiomyocyte membrane Hypothesis: during sepsis, reduced sensitivity of myofilament to Ca ++ due to reduced ability of Ca ++ to combine Tn 1 receptor AMP Adenylate cyclase + PKa Ca 2+ Tn Myosin-Actin bridges + cytosol Ca 2+ sarcoplasmic reticulum

This suggests an alteration of Ca ++ myofilament responsiveness

Mechanisms of sepsis-related cardiac dysfunction Supracellular mechanisms Intrinsic cellular mechanisms Coronary blood flow Circulating factors -adrenergic receptors Calcium and myofilaments Nitric oxide and peroxynitrite pathways

Mechanisms of sepsis-related cardiac dysfunction Supracellular mechanisms Intrinsic cellular mechanisms Coronary blood flow Circulating factors -adrenergic receptors Calcium and myofilaments Nitric oxide and peroxynitrite pathways Apoptosis At the initial phase of sepsis, a cytokine effect mainly contributes to myocardial depression At a later phase, other mechanisms are likely to be predominant

Sepsis-related cardiac dysfunction Incidence Mechanisms Diagnosis Treatment

Diagnosis of sepsis-related cardiac dysfunction a LVEF of 50% suggests a mild myocardial depression if SBP is 130 mmhg. but suggests a profound myocardial depression if SBP is 80 mmhg Echocardiography PiCCO BNP Key method LVEF For a correct interpretation, take also into account the SBP (afterload)

Diagnosis of sepsis-related cardiac dysfunction Echocardiography PiCCO BNP

PiCCO technology Transpulmonary thermodilution 1- Cardiac output CFI: 2- Global end-diastolic volume (GEDV) Index of 3- Cardiac function index (CFI) = CO/GEDV cardiac systolic function

A low CFI can alert the clinician CFI for detecting LVEF 35% 96 simultaneous measurements CFI (PiCCO) and LVEF (echo) and incite to perform an echo

Repetitive measurements of CFI allow following changes in cardiac function with therapy

Diagnosis of sepsis-related cardiac dysfunction Echocardiography PiCCO BNP

Plasma BNP BNP release LV myocyte stretch RV myocyte stretch

In septic patients, BNP levels can be elevated in the absence of LV dysfunction High BNP values Normal LVEF values Sepsis

Inflammatory cytokines (TNF-, IL-1, IL-6) BNP clearance Plasma BNP BNP release LV myocyte stretch RV myocyte stretch

Inflammatory cytokines (TNF-, IL-1, IL-6) BNP clearance Renal failure Plasma BNP BNP release LV myocyte stretch RV myocyte stretch

Sepsis-related cardiac dysfunction Incidence Mechanisms Diagnosis Treatment

Treatment of sepsis-related cardiac dysfunction To treat or not to treat?

However beneficial effects of dobutamine are unpredictable (potential decreased efficacy)

Dobutamine increased LVEF by more than 10% only in 35% of pts

Dobutamine and septic myocardial dysfunction beneficial effects are unpredictable (potential decreased efficacy) detrimental effects may occur (arrhythmias, vasodilation, etc) administration of dobutamine should be restricted to patients: - with low LVEF test the response to dobutamine before any prolonged administration - and low SvO 2 (< 65-70 %) despite fluid resuscitation and vasopressive therapy

Treatment of sepsis-related cardiac dysfunction To treat or not to treat? Alternatives to dobutamine?

cell membrane 1 agonist camp Ca 2+ sensitizers 1 receptor AMP Adenylate cyclase + PKa Ca 2+ Tn Myosin-Actin bridges + cytosol Ca 2+ sarcoplasmic reticulum

ml/m 2 44 42 40 38 36 SI Stroke index * Levosimendan Dobutamine 34 32 Baseline 24 hrs

ml/m 2 LVEF 52 47 42 * * Levosimendan Dobutamine 37 32 27 Baseline 24 hrs

Is Levosimendan the magic drug? Not sure

Treatment of sepsis-related cardiac dysfunction To treat or not to treat? Make sure that the patient is not still hypovolemic assess fluid responsiveness Alternatives to dobutamine? static measures of preload (i.e. CVP) are not appropriate dynamic indices of preload responsiveness are reliable In any case, before giving inotropes Make sure that hypotension is corrected

Conclusion Mechanisms contributing to septic cardiac dysfunction are complex and intricate. Treating or not cardiac dysfunction is still a matter of debate (place of echo and SvO 2 ). In any case, first correct hypovolemia and hypotension. When the decision to treat is made, dobutamine is recommended,. but it can be ineffective in most severe patients. The place of Ca ++ sensitizers needs further evaluation. Thank you